Quality statements
Statement 1 People with suspected breast cancer referred to specialist services are offered the triple diagnostic assessment in a single hospital visit. [2016]
Statement 2 People with biopsy-proven invasive breast cancer or ductal carcinoma in situ (DCIS) are not offered a preoperative MRI scan unless there are specific clinical indications for its use. [2016]
Statement 3 People with early breast cancer are offered a tumour profiling test if it could help when making decisions about chemotherapy. [2016]
Statement 4 People with newly diagnosed invasive breast cancer and those with recurrent breast cancer (if clinically appropriate) have their hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status of the tumour assessed. [2011, updated 2026]
Statement 5 People with breast cancer who develop metastatic disease have their treatment and care managed by a multidisciplinary team. [2011, updated 2016]
Statement 6 People with breast cancer are assigned a key worker. [2011, updated 2026]
In 2016 this quality standard was updated, and statements prioritised in 2011 were updated or replaced (2016). In 2026, changes were made to align this quality standard with the updated NICE guideline on advanced breast cancer: diagnosis and treatment. Changes to statement wording in this alignment are marked as (2011, updated 2026). For more information, see update information.
The previous version of the quality standard for breast cancer is available as a pdf.